{
    "id": 474,
    "fullName": "EZH2 Y641F",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "EZH2 Y641F lies within the SET domain of the Ezh2 protein (UniProt.org). Y641F confers a gain of function to the Ezh2 protein, as demonstrated by altered substrate specificity, increased catalytic efficiency for H3K27 trimethylation (PMID: 21190999, PMID: 21078963), and increased H3K27 trimethylation in breast cancer cell lines (PMID: 25253781).",
            "references": [
                {
                    "id": 2703,
                    "pubMedId": 21078963,
                    "title": "Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21078963"
                },
                {
                    "id": 505,
                    "pubMedId": 21190999,
                    "title": "Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21190999"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 12214,
                    "pubMedId": 25253781,
                    "title": "A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25253781"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2146,
        "geneSymbol": "EZH2",
        "terms": [
            "EZH2",
            "ENX-1",
            "ENX1",
            "EZH2b",
            "KMT6",
            "KMT6A",
            "WVS",
            "WVS2"
        ]
    },
    "variant": "Y641F",
    "createDate": "05/02/2014",
    "updateDate": "09/16/2018",
    "referenceTranscriptCoordinates": {
        "id": 171524,
        "transcript": "NM_001203247",
        "gDna": "chr7:g.148811635T>A",
        "cDna": "c.1922A>T",
        "protein": "p.Y641F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2178,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with EPZ005687 decreased proliferation and induced cell killing in a lymphoma cell line harboring EZH2 Y641F in culture (PMID: 23023262).",
            "molecularProfile": {
                "id": 671,
                "profileName": "EZH2 Y641F"
            },
            "therapy": {
                "id": 2663,
                "therapyName": "EPZ005687",
                "synonyms": null
            },
            "indication": {
                "id": 60058,
                "name": "lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2699,
                    "pubMedId": 23023262,
                    "title": "A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23023262"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7820,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells over expressing EZH2 carrying simultaneous Y641F and Y111D mutations demonstrated reduced sensitivity to Tazemetostat (EPZ-6438) in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26054,
                "profileName": "EZH2 Y111D EZH2 Y641F"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 7819,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells overexpressing EZH2 and carrying simultaneous Y641F and Y111D mutations demonstrated reduced sensitivity to GSK126 in culture (PMID: 26360609).",
            "molecularProfile": {
                "id": 26054,
                "profileName": "EZH2 Y111D EZH2 Y641F"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6504,
                    "pubMedId": 26360609,
                    "title": "Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26360609"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 671,
            "profileName": "EZH2 Y641F",
            "profileTreatmentApproaches": [
                {
                    "id": 7417,
                    "name": "EZH2 inhibitor",
                    "profileName": "EZH2 Y641F"
                }
            ]
        },
        {
            "id": 26054,
            "profileName": "EZH2 Y111D EZH2 Y641F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 171524,
            "transcript": "NM_001203247",
            "gDna": "chr7:g.148811635T>A",
            "cDna": "c.1922A>T",
            "protein": "p.Y641F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 171525,
            "transcript": "XM_011515889",
            "gDna": "chr7:g.148810374T>A",
            "cDna": "c.1922A>T",
            "protein": "p.Y641F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}